Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.79 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.77 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TYMP | P19971 | 2/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.37 |
| ▸ | POLG | P54098 | 2/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cidofovir Diposphate SCHEMBL29390031 | 0.95 | FGFR1 (0.74) | FGFR1SLC22A6POLBTYMPHPRT1 | |
| Cidofovir Anhydrous SCHEMBL934590 | 0.91 | FGFR1 (0.91) | FGFR1SLC22A6POLBTYMPHPRT1 | |
| SCHEMBL13815423 | 0.89 | FGFR1 (0.72) | FGFR1SLC22A6POLBTYMPHPRT1 | |
| SCHEMBL12950769 | 0.89 | FGFR1 (0.79) | FGFR1SLC22A6POLBTYMPHPRT1 | |
| Cidofovir Anhydrous SCHEMBL14682730 | 0.88 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1NT5E | |
| Cidofovir Anhydrous SCHEMBL3948 | 0.88 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1NT5E | |
| Cidofovir Anhydrous SCHEMBL1389452 | 0.88 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1NT5E | |
| Cidofovir Anhydrous SCHEMBL151807 | 0.88 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1NT5E | |
| SCHEMBL13815425 | 0.87 | FGFR1 (0.70) | FGFR1SLC22A6POLBTYMPHPRT1 | |
| Cidofovir Anhydrous SCHEMBL2946566 | 0.87 | SLC22A6 (1.00) | FGFR1SLC22A6TYMPHPRT1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485131-B2 | Formulations of brincidofovir | EMERGENT BIODEFENSE OPERATIONS LANSING LLC (US) | 2025-12-02 | — | — | US | disclosed |
| EP-3474822-B1 | FORMULATIONS OF BRINCIDOFOVIR | EMERGENT BIODEFENSE OPERATIONS LANSING LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| CN-119139329-A | Preparation of brinzdofovir | 应急生物防御行动兰辛有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-118416082-A | Preparation of brinzdofovir | 应急生物防御行动兰辛有限责任公司 | 2024-08-02 | — | — | CN | disclosed |
| EP-4295853-A2 | FORMULATIONS OF BRINCIDOFOVIR | Emergent BioDefense Operations Lansing LLC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230210873-A1 | FORMULATIONS OF BRINCIDOFOVIR | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2023-07-06 | — | — | US | disclosed |
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-06-08 | — | — | US | disclosed |
| CN-114569547-A | Preparation of brinciclovir | 奇默里克斯公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210873-A1 | FORMULATIONS OF BRINCIDOFOVIR | SAMHD1, UGT2B7, HPRT1 | FGFR1 1658/4885SLC22A6 523/4885POLB 751/4885 |
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | PNP, TYMP, ENPP1 | FGFR1 1039/4885SLC22A6 926/4885POLB 204/4885 |
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | ACE, ACE2, PNP | FGFR1 4184/4885SLC22A6 3129/4885POLB 34/4885 |
| US-12485131-B2 | Formulations of brincidofovir | SAMHD1, UGT2B7, HPRT1 | FGFR1 1658/4885SLC22A6 523/4885POLB 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.